How long does it take to become resistant to sotorazeb? How to deal with it?

Sotorasib (Sotorasib) has shown good efficacy in the treatment of patients with non-small cell lung cancer (NSCLC) carrying KRAS G12C mutations, but there is a common problem of drug resistance to targeted drugs. Generally speaking, patients may develop drug resistance after taking sotorasiib for several months to a year, and this time varies between individuals. After the emergence of drug resistance, sotoraxib may not be able to continue to inhibit the growth of cancer cells, and the patient's condition may progress again. The following are the causes and management strategies of sotoraxib resistance.

1. Causes of drug resistance to sotoraxib

Secondary mutation of KRAS G12C mutation: During the long-term use of sotoraxib, the KRAS gene may undergo new mutations, which will change the structure of the KRAS protein, causing sotoraxib to lose its effect on it.

Straditional pathway activation: Cancer cells may circumvent the inhibitory effect of KRAS by activating other signaling pathways (such as EGFR, MET, etc.), allowing cells to continue to proliferate, although sotoraxib still inhibits KRAS.

Cell adaptability mechanism: Cancer cells have extremely strong adaptability and may reduce the therapeutic effect of sotorasibu by increasing drug resistance-related proteins and repairing DNA damage.

2. Strategies for dealing with drug resistance

Combination therapy: After drug resistance occurs, doctors usually consider a combination therapy strategy. For example, sotoraxib can be used in combination with other targeted drugs (such as EGFR inhibitors) or immunotherapy drugs to block multiple signaling pathways, thereby reducing the risk of drug resistance. Combination therapy has shown good results in clinical trials, but the specific combination needs to be determined based on the specific situation of the patient.

Changing targeted drugs: If sotorasiib resistance is strong and there are no other effective targeted drug combinations, doctors may consider changing the treatment plan. For patients with mutations in other molecular targets other than KRAS mutations (such as MET, PI3K, etc.), corresponding targeted drugs can be selected to replace sotoraxib. New KRAS G12C inhibitors may also be available in the future to provide alternatives for drug-resistant patients.

Re-do genetic testing: After drug resistance, patients should undergo detailed genetic testing to determine whether new mutations or gene expression changes have occurred. Genetic testing can help doctors find new treatment targets and develop personalized treatment plans. For example, if activation of the EGFR or MET auxiliary pathway is detected, an EGFR or MET inhibitor can be added to sotoracib.

Chemotherapy and immunotherapy: In cases where sotorasib and other targeted treatments have failed, doctors may recommend traditional chemotherapy or immunotherapy. Although chemotherapy has serious side effects, it may still be effective for some patients. Immunotherapy activates the body's immune system to attack cancer cells and is suitable for some drug-resistant patients.

3. How to delay the occurrence of drug resistance

In order to delay the development of drug resistance to sotoraxib, patients should review it regularly and follow their doctor's instructions during use. The following methods may help delay drug resistance:

Regular follow-up: Patients should undergo regular follow-up examinations, including imaging examinations and biomarker monitoring, in order to detect signs of drug resistance as early as possible and adjust treatment strategies in a timely manner.

Reasonable dose control: Avoid adjusting the dose on your own, and take it strictly in accordance with the doctor's instructions to avoid drug resistance caused by overdose or deficiency.

Lifestyle management: Maintaining a healthy lifestyle, a balanced diet and appropriate exercise may have a positive impact on the efficacy of drugs and enhance the patient's overall anti-cancer ability.

Resistance to sotoraxib is a complex problem. Once resistance occurs, patients may need to receive combination therapy, adjust drugs, or undergo genetic testing to select new treatment options. With reasonable treatment plans and timely adjustments, some patients can continue to achieve effective disease control. Under the guidance of clinicians, patients can obtain corresponding support and alternatives when drug resistance occurs to extend survival and improve quality of life.